Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 8 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(33.3%)

Phase 3

3(33.3%)

Phase 2

3(33.3%)

9Total

Phase 1(3)

Phase 3(3)

Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07216430Phase 2Recruiting

Safety and Efficacy of wSp Vaccine in Young Children

Role: lead

NCT04387409Phase 3Completed

Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Role: lead

NCT07059182Phase 1Completed

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

Role: lead

NCT04351685Phase 3Completed

Evaluation of Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Tb Infection in Infants

Role: collaborator

NCT04435379Phase 3Completed

Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic

Role: lead

NCT02391415Phase 2Completed

Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa

Role: collaborator

NCT01479972Phase 2Completed

Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa

Role: lead

NCT01113281Phase 1Completed

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison to BCG in Healthy Volunteers in South Africa

Role: lead

NCT00749034Phase 1Completed

Dose-Escalation Study on Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers

Role: lead

All 9 trials loaded